查看全部

肿瘤

急性髓系白血病

肾上腺皮质癌

膀胱尿路上皮癌

Review

系统性综述与网络荟萃分析：lorlatinib作为一线治疗ALK阳性晚期非小细胞肺癌（NSCLC）与其他ALK酪氨酸激酶抑制剂（TKIs）比较

Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC)

DOI 原文链接

用sci-hub下载

LUNG CANCER

正在获取期刊数据...

发表日期:2024 Nov

作者:

DOI:10.1016/j.lungcan.2024.107968

摘要

AI正在翻译并加载中文摘要...

系统性综述与网络荟萃分析：lorlatinib作为一线治疗ALK阳性晚期非小细胞肺癌（NSCLC）与其他ALK酪氨酸激酶抑制剂（TKIs）比较

Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC)

摘要

Abstract